‘Made in Chandigarh’ technology to bring down prices of insulin and Hepatitis B vaccine
Advertisement
Advertisement
If everything at the Presently India has to depend on patented technology of the foreign countries to produce insulin, streptokinase and hepatitis B etc. With 66 million diabetics and 40 million hepatitis B patients in the country, this will be a major reliever for many.
Pichia is the vector that is currently used in insulin.
"Because Pichia is patented, Indian biotech companies have to pay the inventor, which adds to the cost of the vaccine. Thus, we felt the need to develop new expression systems," Dr
Pichia vector is generally licensed for commercial research for $50,000 with annual maintenance fee of $5000 to $30,000. In case the product is commercialized, the fee is $75,000 plus royalty ranging between 3% and 5%.
Advertisement
The present cost of hepatitis B vaccine in India ranges between Rs 45 (
"So far we have expressed hepatitis B vaccine at laboratory scale level in fission yeast. Once the production is scaled up, the production cost is estimated to be around Re 1 per dose, while the lowest production cost reported for Pichia-based system is Rs. 4 per dose and the lowest
Advertisement
- Welcome to the white-collar recession
- Singapore Airlines was ordered to pay a couple compensation for 'mental agony' after they complained their business-class seats didn't automatically recline
- A 101-year-old woman keeps getting mistaken for a baby on flights and says it's because American Airlines' booking system can't handle her age
- “Wish to follow in the footsteps of PM Modi!” ‘Anupamaa’ star Rupali Ganguly joins BJP
- “Wish to follow in the footsteps of PM Modi!” ‘Anupamaa’ star Rupali Ganguly joins BJP
- Assassin’s Creed Mirage on iPhone 15: Killer game to debut on Pro and iPad on June 6
- 5 worst cooking oils for your health
- From fiber to protein: 10 health benefits of including lentils in your diet
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market